Orphagen Pharmaceuticals Inc. has presented SF1 (NR5A1) receptor antagonists reported to be useful for the treatment of cancer, endocrine disease and endometriosis.
Adlai Nortye Ltd. has described mitogen-activated protein kinase kinase kinase kinase 1 (MAP4K1) inhibitors reported to be useful for the treatment of cancer, immunological and inflammatory disorders.
Hangzhou Apeloa Medicine Research Institute Co. Ltd. and Apeloa Pharmaceutical Co. Ltd. have disclosed fibroblast growth factor receptor 4 (FGFR-4) inhibitors reported to be useful for the treatment of cancer.
Investigators from the University of Copenhagen, Denmark have developed a cell line engineered to express bone morphogenetic protein 2 (BMP-2) and key extracellular matrix genes and critical factors that regulate and support human hematopoiesis. The findings were reported in the Oct. 12, 2022, issue of Science Translational Medicine. One of the clinical applications that the research team is interested in involves exploiting the MSOD-B hOss as a tumor model for bone colonization in the context of various cancers.
About 50% of patients with lung cancer present with metastatic disease; researchers have shown that breast cancer metastasis-suppressor 1 (BRMS1) suppresses metastases in non-small-cell lung cancer and other solid tumors due to its ability to function in a multiprotein histone deacetylase transcriptional corepressor complex or as an E3 ligase to control the degradation of p300 acetyltransferase.
Shanghai Qilu Pharmaceutical Research and Development Centre Ltd. has described proteolysis targeting chimera (PROTAC) compounds comprising an E3 ubiquitin ligase-binding moiety covalently linked to epidermal growth factor receptor (EGFR)-binding moiety through linker reported to be useful for the treatment of cancer.
Nutshell Biotech (Shanghai) Co. Ltd. has discovered fibroblast growth factor receptor (FGFR) inhibitors reported to be useful for the treatment of cancer.
RSS
